We are live on ! Find out more
XRTX icon

XORTX Therapeutics
XRTX

6 hedge funds and large institutions have $92.8K invested in XORTX Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,471% more capital inflows, than outflows

Capital inflows: $96.4K | Capital outflows: $6.14K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding

Funds holding: 3 → 6 (+3)

2.12% more ownership

Funds ownership: 0.22% → 2.34% (+2.1%)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$55.2K
2
StoneX Group
StoneX Group
New York
+$39.1K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.75K
4
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$387

Top Sellers

Rank Fund Capital Flow
1
Kingsview Wealth Management
Kingsview Wealth Management
Oregon
-$6.14K

XRTX Hedge Fund Activity: Q2 2026 in Review

6 of the 8,367 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q2 2026, worth a combined $92.8K — up 1,386% from $6.25K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XRTX positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $55.2K. The largest seller was Kingsview Wealth Management, exiting entirely with an estimated $6.14K sold.

  • 6 institutional investors held XORTX Therapeutics (XRTX) as of Q2 2026, up from 3 in Q1 2026.
  • Funds reported $92.8K of XORTX Therapeutics stock for Q2 2026, up 1,386% quarter-over-quarter.
  • 4 funds opened new XORTX Therapeutics positions in Q2 2026 and 1 closed out, a net change of +3 holders.
  • The largest XORTX Therapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $55.2K added.
  • The largest XORTX Therapeutics seller in Q2 2026 was Kingsview Wealth Management, an estimated $6.14K sold.

Based on aggregated 13F filings for Q2 2026.